GSK (LSE: GSK) acquired CureVac's (NASDAQ: CVAC) share in joint flu and COVID-19 vaccine projects, enhancing its mRNA tech expertise. CureVac's stock surged 24%, extending its financial runway to 2028 but will cut 30% of its workforce to focus on cancer therapies.
